Yes, Suboxone Can Cause Serious Dental Problems
Suboxone (buprenorphine/naloxone) sublingual formulations are associated with significant dental disease, including tooth decay, cavities, tooth sensitivity, and tooth loss, and patients must be counseled about this risk and implement rigorous preventive oral hygiene measures.
The Evidence for Dental Harm
The FDA issued a safety warning in 2022 specifically about oral health problems with transmucosal (sublingual and buccal) buprenorphine formulations 1. This is not a theoretical concern—multiple high-quality recent studies confirm this association:
The most compelling evidence comes from a 2025 propensity score-weighted survival analysis showing patients with opioid use disorder prescribed transmucosal buprenorphine had a 1.24-1.30 times higher risk of developing new oral health problems at both 1-year and 5-year follow-up compared to those not on buprenorphine 2. This study analyzed over 720,000 adults with OUD, making it the largest and most robust examination of this issue.
Why This Happens: The Mechanism
The dental damage occurs through multiple mechanisms specific to the sublingual/buccal route:
Prolonged oral exposure: A 2025 rat study demonstrated that sublingual administration causes significantly greater buprenorphine accumulation in salivary glands compared to intravenous administration, leading to prolonged drug exposure in oral fluids 3
Direct bacterial effects: Groundbreaking 2026 research showed that buprenorphine directly enhances Streptococcus mutans (the primary cavity-causing bacteria) virulence by upregulating genes for biofilm formation and extracellular matrix production, creating thicker, more cariogenic biofilms 4
Route-specific risk: A 2024 FDA adverse event database analysis found disproportionate dental disorder reporting for sublingual (ROR 20.03), buccal (ROR 4.46), and oral (ROR 7.17) routes, but NOT for other administration routes like injection 5
Critical Clinical Implications
The formulation matters tremendously:
- Sublingual buprenorphine/naloxone combination: ROR 19.47 for dental disorders 5
- Sublingual buprenorphine monotherapy: ROR 23.55 for dental disorders 5
- Injectable buprenorphine: No signal for dental problems 5
Common Pitfall to Avoid:
Do not dismiss patient complaints about tooth problems as unrelated to their medication. The FDA adverse event data shows this is a real, medication-specific effect 1, 5.
What Patients Need to Do
Patients on sublingual Suboxone must implement aggressive preventive measures:
- Proper administration technique: After the film/tablet dissolves completely, rinse mouth thoroughly with water and swallow
- Wait at least 1 hour before brushing teeth after taking the medication
- Maintain excellent daily oral hygiene with fluoride toothpaste
- Regular dental examinations and professional cleanings
- Consider switching to long-acting injectable buprenorphine if dental problems develop 3
The Risk-Benefit Context
While the dental risks are real and significant, this should not deter patients from using buprenorphine for opioid use disorder treatment. Buprenorphine remains a gold standard, life-saving treatment that decreases opioid-related mortality 3. The key is informed consent, preventive strategies, and close monitoring.
Patients with longer duration of heroin use already have substantially impaired oral health (mean DMFT score 19.1) and poor oral hygiene before starting treatment 6, so the buprenorphine effect compounds an existing problem rather than creating it de novo.
The solution is not to avoid buprenorphine, but to integrate prevention-oriented dental care into addiction treatment services and have frank discussions with patients about oral hygiene practices that can mitigate risk 2, 6.